IIM
TRVI icon

INTECH Investment Management’s Trevi Therapeutics TRVI Stock Holding History

INTECH Investment Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431K Buy
23,102
+1,251
+6% +$18.2K ﹤0.01% 1410
2026
Q1 		$261K Sell
21,851
-7,219
-25% -$80.8K ﹤0.01% 1626
2025
Q4 		$364K Buy
29,070
+3,741
+15% +$43.2K ﹤0.01% 1660
2025
Q3 		$232K Sell
25,329
-17,680
-41% -$133K ﹤0.01% 1982
2025
Q2 		$235K Buy
43,009
+20,994
+95% +$131K ﹤0.01% 2005
2025
Q1 		$138K Sell
22,015
-5,648
-20% -$26.9K ﹤0.01% 2221
2024
Q4 		$114K Buy
27,663
+8,749
+46% +$28K ﹤0.01% 2188
2024
Q3 		$63.2K Buy
+18,914
New +$56.2K ﹤0.01% 1959

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

INTECH Investment Management's TRVI Position: Q2 2026 in Review

INTECH Investment Management increased its Trevi Therapeutics (TRVI) stake by 5.7% in Q2 2026, buying an estimated $18.2K and bringing the position to 23,102 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #1410.

INTECH Investment Management first reported a position in TRVI in Q3 2024 and has held it in 8 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • INTECH Investment Management held 23,102 shares of Trevi Therapeutics worth $431K as of Q2 2026.
  • INTECH Investment Management bought 1,251 Trevi Therapeutics shares in Q2 2026, an estimated $18.2K.
  • Trevi Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1410 holding.
  • INTECH Investment Management first reported a position in Trevi Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.